Prostaglandins and aminoglycoside nephrotoxicity

The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was stud...

Full description

Saved in:
Bibliographic Details
Published inToxicology and applied pharmacology Vol. 78; no. 3; p. 386
Main Authors Assael, B M, Chiabrando, C, Gagliardi, L, Noseda, A, Bamonte, F, Salmona, M
Format Journal Article
LanguageEnglish
Published United States 01.05.1985
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was studied measuring creatinine clearance, blood urea nitrogen (BUN), and serum electrolytes, urine osmolality, and maximal urinary concentrating capacity after water deprivation and vasopressin administration. Gentamicin toxicity on the proximal tubule was evaluated by measuring urinary excretion of the lysosomal enzyme N-acetylglucosaminidase (NAG). Renal prostaglandin (PG) production was evaluated measuring the concentration of PGE2, PGD2, PGF2 alpha, 6-keto-PGF1 alpha, and thromboxane B2 (TXB2) in whole renal homogenate after a 15-min incubation at 37 degrees C using gas chromatography-mass spectrometry. Gentamicin alone reduced the glomerular filtration rate (GFR) 20 to 30% after 5 and 10 days of treatment. Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment. Similarly, gentamicin reduced the urinary concentrating capacity and addition of ASA worsened the effects. Gentamicin markedly increased NAG excretion but this effect was reduced by ASA, probably as a result of lysosomal stabilization. ASA alone inhibited the production of prostaglandins in renal tissue by 70 to 90% after single or multiple doses. The animals treated with gentamicin alone presented a significant, specific increase in PGE2 production after 10 days of treatment but this increase did not occur when the two compounds were given together. Since PGE2 has a vasodilatory effect in the kidney these results suggest that it may play a specific role in maintaining normal renal blood flow and GFR during the development of aminoglycoside nephrotoxicity. The inhibition of prostaglandin production by nonsteroid anti-inflammatory drugs prevents this compensatory mechanism and worsens the renal damage.
AbstractList The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was studied measuring creatinine clearance, blood urea nitrogen (BUN), and serum electrolytes, urine osmolality, and maximal urinary concentrating capacity after water deprivation and vasopressin administration. Gentamicin toxicity on the proximal tubule was evaluated by measuring urinary excretion of the lysosomal enzyme N-acetylglucosaminidase (NAG). Renal prostaglandin (PG) production was evaluated measuring the concentration of PGE2, PGD2, PGF2 alpha, 6-keto-PGF1 alpha, and thromboxane B2 (TXB2) in whole renal homogenate after a 15-min incubation at 37 degrees C using gas chromatography-mass spectrometry. Gentamicin alone reduced the glomerular filtration rate (GFR) 20 to 30% after 5 and 10 days of treatment. Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment. Similarly, gentamicin reduced the urinary concentrating capacity and addition of ASA worsened the effects. Gentamicin markedly increased NAG excretion but this effect was reduced by ASA, probably as a result of lysosomal stabilization. ASA alone inhibited the production of prostaglandins in renal tissue by 70 to 90% after single or multiple doses. The animals treated with gentamicin alone presented a significant, specific increase in PGE2 production after 10 days of treatment but this increase did not occur when the two compounds were given together. Since PGE2 has a vasodilatory effect in the kidney these results suggest that it may play a specific role in maintaining normal renal blood flow and GFR during the development of aminoglycoside nephrotoxicity. The inhibition of prostaglandin production by nonsteroid anti-inflammatory drugs prevents this compensatory mechanism and worsens the renal damage.
Author Gagliardi, L
Bamonte, F
Noseda, A
Salmona, M
Assael, B M
Chiabrando, C
Author_xml – sequence: 1
  givenname: B M
  surname: Assael
  fullname: Assael, B M
– sequence: 2
  givenname: C
  surname: Chiabrando
  fullname: Chiabrando, C
– sequence: 3
  givenname: L
  surname: Gagliardi
  fullname: Gagliardi, L
– sequence: 4
  givenname: A
  surname: Noseda
  fullname: Noseda, A
– sequence: 5
  givenname: F
  surname: Bamonte
  fullname: Bamonte, F
– sequence: 6
  givenname: M
  surname: Salmona
  fullname: Salmona, M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/4049389$$D View this record in MEDLINE/PubMed
BookMark eNo9zk9LwzAYx_EcJnObvgOFHvUQ9-Rfmxxl-A8G86DgbaTJ0xlpk9JUsO_egcPTB76HH78lmcUUkZArBncMWLkGkIwC6I8brW4NcCmpmJHFfz4ny5y_AMBIyeZkLkEaoc2CwOuQ8mgPrY0-xFwcKWwXYjq0k0s5eCwi9p9DGtNPcGGcLshZY9uMlydX5P3x4W3zTLe7p5fN_ZY6ocuRMit4Bd6YulEVtxpZUyrnlUKGinuUNUNtmgo4cIfOlFXthKgao-Co83xFrv92---6Q7_vh9DZYdqfnvNfy3hGng
CitedBy_id crossref_primary_10_1038_ki_2010_337
crossref_primary_10_1128_AAC_43_5_1003
crossref_primary_10_1590_S0100_879X2004000700006
crossref_primary_10_1016_S0195_5616_88_50128_6
crossref_primary_10_1111_j_1476_4431_2005_00167_x
crossref_primary_10_1007_s10620_006_3145_8
crossref_primary_10_1002_ppul_1047
crossref_primary_10_1177_20420986211041277
crossref_primary_10_1016_S0024_3205_98_00070_8
crossref_primary_10_1179_joc_2001_13_5_461
crossref_primary_10_1016_0306_3623_95_00049_6
crossref_primary_10_1002_jps_2600830419
crossref_primary_10_1080_00039896_1990_9940810
crossref_primary_10_1111_j_0265_0215_1998_00269_x
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/0041-008X(85)90244-3
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 4049389
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.55
.GJ
.HR
.~1
0R~
123
1B1
1RT
1~.
1~5
29Q
3O-
4.4
457
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIKC
AAIKJ
AAKOC
AALRI
AAMNW
AAOAW
AAQFI
AAQXK
AAXKI
AAXUO
ABEFU
ABFNM
ABFRF
ABFYP
ABJNI
ABLST
ABMAC
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFFNX
AFJKZ
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHEUO
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AKIFW
AKRWK
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLECG
BLXMC
C45
CAG
CGR
COF
CS3
CUY
CVF
DM4
EBS
ECM
EFBJH
EIF
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IHE
J1W
KCYFY
KOM
LG5
M33
M41
MO0
N9A
NPM
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSJ
SSP
SSZ
T5K
TEORI
TWZ
UHS
WH7
WUQ
X7M
XJT
XPP
Y6R
YCJ
ZGI
ZKB
ZMT
ZU3
ZXP
~G-
~KM
ID FETCH-LOGICAL-c386t-1a3270d99bf572a8e1f65cd55e1e52de4b1e89f70202cec967bc337f950c33cd2
ISSN 0041-008X
IngestDate Sat Sep 28 08:42:06 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c386t-1a3270d99bf572a8e1f65cd55e1e52de4b1e89f70202cec967bc337f950c33cd2
PMID 4049389
ParticipantIDs pubmed_primary_4049389
PublicationCentury 1900
PublicationDate 1985-May
PublicationDateYYYYMMDD 1985-05-01
PublicationDate_xml – month: 05
  year: 1985
  text: 1985-May
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Toxicology and applied pharmacology
PublicationTitleAlternate Toxicol Appl Pharmacol
PublicationYear 1985
SSID ssj0009441
Score 1.3855807
Snippet The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were...
SourceID pubmed
SourceType Index Database
StartPage 386
SubjectTerms Analysis of Variance
Animals
Aspirin - pharmacology
Blood Urea Nitrogen
Body Weight - drug effects
Creatinine - metabolism
Drug Interactions
Gas Chromatography-Mass Spectrometry
Gentamicins - toxicity
Glomerular Filtration Rate - drug effects
Injections, Intraperitoneal
Kidney Cortex - drug effects
Kidney Cortex - metabolism
Kidney Cortex - pathology
Male
Prostaglandins - biosynthesis
Prostaglandins D - biosynthesis
Prostaglandins D - urine
Prostaglandins E - biosynthesis
Prostaglandins E - urine
Prostaglandins F - biosynthesis
Prostaglandins F - urine
Rats
Title Prostaglandins and aminoglycoside nephrotoxicity
URI https://www.ncbi.nlm.nih.gov/pubmed/4049389
Volume 78
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEA-nIggifqKnHnnw5ERzNm3TJI963CkHJ_uwwr5JkiZSONsF-3DeX3-TprttvQ_0XtqSsCHkNzudmc5vBqGjOM1trrQkvpgaAaEQRGiuCSi-zLoo0cL50MC3m-z6Nv06YZMuib1hl9T6o_n5R17J_6AKY4CrZ8m-Atn5ojAAz4AvXAFhuL4I45GnbKimC4fPdGnqrj4UZXX__clUvg_naWkBrKqufhSmqAdfcMd-rCvApFprdNqVsp4H2wFCFT7mX5728gEKBZ52mQ9jrVewncJLXcdoaBJoHwGrLnSaB96dYF1S30x1ppSAwTDpq04ueiKS9PRgEupb_6afQ6hgvhYY0YK9929EsDJI0v8JnPT0ocEtBScmCX2G_jn5rG52O7OAFrjwCvDGh3Fm1ZjTNLRSbPcx41TS7Hw-9kGwk3ZfK2i5Xe2Z89EYIeN1tNZ6D_giiMIGemPLTXQ8Cpg9neFxx6Z7PMPHeNRDcxOthhgtDtSzLRQN5QfDDQ_lBw_lZxvdfvk8_nRN2g4axAACNaEqiXmUS6kd47ESlrqMmZwxSy2Lc5tqaoV0HHyG2FgjM65NknAnWQR3k8c7aLGsSruLsDGGWkO9uwAGjZOaRTGXVEmhlXM820M74WTupqFMyl17ZG__NrGPVjpBO0BLDv6V9hBMvFq_a-D6BUvpTWE
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostaglandins+and+aminoglycoside+nephrotoxicity&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Assael%2C+B+M&rft.au=Chiabrando%2C+C&rft.au=Gagliardi%2C+L&rft.au=Noseda%2C+A&rft.date=1985-05-01&rft.issn=0041-008X&rft.volume=78&rft.issue=3&rft.spage=386&rft_id=info:doi/10.1016%2F0041-008X%2885%2990244-3&rft_id=info%3Apmid%2F4049389&rft_id=info%3Apmid%2F4049389&rft.externalDocID=4049389
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon